J.T. Beck

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

Tibor Csőszi, Marina Maglakelidze, Robert J. Hoyer et al. · Annals of Oncology · 2019 · 169 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)

Timothy F. Cloughesy, Andrew Brenner, John de Groot et al. · Neuro-Oncology · 2019 · 72 citations · Full text

Medicine, Oncology, Pharmacology +15

A mathematical model of low grade gliomas treated with temozolomide and its therapeutical implications

Magdalena Bogdańska, Marek Bodnar, Juan Belmonte-Beitia et al. · Mathematical Biosciences · 2017 · 39 citations

Medicine, Oncology, Pharmacology +16

Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma

Patrick Y. Wen, Jordi Rodón, Warren Mason et al. · ESMO Open · 2020 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC).

G. R. Blumenschein, Fairooz F. Kabbinavar, Hari Menon et al. · Journal of Clinical Oncology · 2010 · 16 citations

Medicine, Pharmacology, Pharmacotherapy +17